Bank of New York Mellon’s Oruka Therapeutics ORKA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$13.4M Buy
140,870
+33,987
+32% +$2.26M ﹤0.01% 1876
2026
Q1
$5.24M Sell
106,883
-7,290
-6% -$253K ﹤0.01% 2292
2025
Q4
$3.46M Buy
114,173
+43,541
+62% +$1.21M ﹤0.01% 2525
2025
Q3
$1.36M Buy
70,632
+7,123
+11% +$106K ﹤0.01% 3031
2025
Q2
$712K Buy
+63,509
New +$662K ﹤0.01% 3315

Other funds holding ORKA

Bank of New York Mellon's ORKA Position: Q2 2026 in Review

Bank of New York Mellon increased its Oruka Therapeutics (ORKA) stake by 32% in Q2 2026, buying an estimated $2.26M and bringing the position to 140,870 shares worth $13.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1876.

Bank of New York Mellon first reported a position in ORKA in Q2 2025 and has held it in 5 quarters since. 159 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Bank of New York Mellon held 140,870 shares of Oruka Therapeutics worth $13.4M as of Q2 2026.
  • Bank of New York Mellon bought 33,987 Oruka Therapeutics shares in Q2 2026, an estimated $2.26M.
  • Oruka Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1876 holding.
  • Bank of New York Mellon first reported a position in Oruka Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 159 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.